Tumor-derived TGF-beta Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas Cancer

Overview

Journal J Immunother

Specialty Allergy & Immunology

Date 2009 Mar 25

PMID 19307989

Citations 85

Authors

Tricia A Moo-Young

Justin W Larson

Brian A Belt

Marcus C Tan

William G Hawkins

Timothy J Eberlein

Peter S Goedegebuure

David C Linehan

Affiliations

Soon will be listed here.

Abstract

CD4+25+Foxp3+ regulatory T cells (Treg) play a critical role in the induction of tolerance to tumor-associated antigens and suppression of antitumor immunity. How Treg are induced in cancer is poorly understood. We reported previously that Treg are significantly elevated in the peripheral blood of patients with pancreas cancer and that in a murine pancreas cancer model induction of Treg seems to be transforming growth factor (TGF)-beta dependent. Here we provide additional evidence that Treg are increased locally within the tumor microenvironment by a mechanism that seems dependent on TGF-beta receptor expression and the presence of tumor derived TGF-beta. The murine pancreas cancer cell line Pan02 produces high levels of TGF-beta both in vitro and in vivo. In contrast, the esophageal murine cancer cell line, Eso2, does not. Immunohistochemical staining of Foxp3 in explanted tumors shows an identifiable population of Treg in the Pan02 (TGF-beta positive) tumors but not Eso2 (TGF-beta negative). Naive CD4+25-Foxp3- T cells, when adoptively transferred into Rag-/- mice, are converted into Foxp3+ Treg in the presence of Pan02 but not Eso2 tumors. Induction of Treg in Pan02 mice is blocked by systemic injection of an anti-TGF-beta antibody. If Rag-/- mice are instead reconstituted with naive CD4+25- T cells expressing a mutated TGF-beta receptor, induction of Foxp3+ Treg in Pan02 bearing mice is blocked. Collectively, these observations further support the role of TGF-beta in the induction of Treg in pancreas adenocarcinoma.

Citing Articles

The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling.

Perez-Penco M, Byrdal M, Lara de la Torre L, Ballester M, Khan S, Siersbaek M Cell Mol Immunol. 2024; 22(1):111-126.

PMID: 39653766 PMC: 11685413. DOI: 10.1038/s41423-024-01238-7.

Spatial analyses revealed S100P + TFF1 + tumor cells in spread through air spaces samples correlated with undesirable therapy response in non-small cell lung cancer.

Fan G, Xie T, Yang M, Li L, Tang L, Han X J Transl Med. 2024; 22(1):917.

PMID: 39385235 PMC: 11462816. DOI: 10.1186/s12967-024-05722-6.

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.

LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma.

Dai S, Peng Y, Wang G, Chen C, Chen Q, Yin L Cell Death Differ. 2024; 32(2):271-290.

PMID: 39143228 PMC: 11803110. DOI: 10.1038/s41418-024-01358-7.

Breast cancer stem cells generate immune-suppressive T regulatory cells by secreting TGFβ to evade immune-elimination.

Mukherjee S, Chakraborty S, Basak U, Pati S, Dutta A, Dutta S Discov Oncol. 2023; 14(1):220.

PMID: 38038865 PMC: 10692020. DOI: 10.1007/s12672-023-00787-z.

References

Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig M, von Boehmer H . Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005; 6(12):1219-27. DOI: 10.1038/ni1265. View

Elliott R, Blobe G . Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005; 23(9):2078-93. DOI: 10.1200/JCO.2005.02.047. View

Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes M, Rebelo M, Demengeot J . Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U S A. 2005; 102(11):4091-6. PMC: 554795. DOI: 10.1073/pnas.0408679102. View

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

Barao I, Hanash A, Hallett W, Welniak L, Sun K, Redelman D . Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006; 103(14):5460-5. PMC: 1459377. DOI: 10.1073/pnas.0509249103. View

Peng Y, Laouar Y, Li M, Green E, Flavell R . TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A. 2004; 101(13):4572-7. PMC: 384788. DOI: 10.1073/pnas.0400810101. View

Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K . Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007; 120(12):2723-33. DOI: 10.1002/ijc.22617. View

Wolf A, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B . Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003; 9(2):606-12. View

Cassis L, Aiello S, Noris M . Natural versus adaptive regulatory T cells. Contrib Nephrol. 2004; 146:121-131. DOI: 10.1159/000082072. View

10.

Petty C, Tompkins M, Tompkins W . Transforming growth factor-beta/transforming growth factor-betaRII signaling may regulate CD4+CD25+ T-regulatory cell homeostasis and suppressor function in feline AIDS lentivirus infection. J Acquir Immune Defic Syndr. 2007; 47(2):148-60. DOI: 10.1097/QAI.0b013e318160df70. View

11.

Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y . Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control. 2006; 17(8):1077-82. DOI: 10.1007/s10552-006-0048-0. View

12.

Liyanage U, Goedegebuure P, Moore T, Viehl C, Moo-Young T, Larson J . Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006; 29(4):416-24. DOI: 10.1097/01.cji.0000205644.43735.4e. View

13.

DeLong P, Carroll R, Henry A, Tanaka T, Ahmad S, Leibowitz M . Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 2005; 4(3):342-6. DOI: 10.4161/cbt.4.3.1644. View

14.

Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N . Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol. 2004; 114(1):52-60. DOI: 10.1016/j.clim.2004.09.007. View

15.

Lee J, Lee K, Kim D, Heo D . Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004; 172(12):7335-40. DOI: 10.4049/jimmunol.172.12.7335. View

16.

Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside T . Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother. 2007; 56(9):1429-42. PMC: 11031003. DOI: 10.1007/s00262-007-0280-9. View

17.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

18.

Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H . Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003; 9(12):4404-8. View

19.

Jarnicki A, Lysaght J, Todryk S, Mills K . Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006; 177(2):896-904. DOI: 10.4049/jimmunol.177.2.896. View

20.

Powell Jr D, Attia P, Ghetie V, Schindler J, Vitetta E, Rosenberg S . Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother. 2008; 31(2):189-98. PMC: 3480218. DOI: 10.1097/CJI.0b013e31815dc0e8. View